World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
WGO IRRITABLE BOWEL SYNDROME (IBS) CASCADES Cascade Options for Resource-sensitive IBS Diagnosis High Resource Levels History, physical examination, exclusion of alarm symptoms, consideration of psychological factors. Full blood count (FBC), erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), stool studies (white blood cells, ova, parasites, occult blood). Selenium homocholic acid taurine (tauroselcholic acid) test (SeHCAT; incorporating selenium-75) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss. This test may have limited availability, even in areas with high resources. Thyroid function. Tissue transglutaminase antibody to screen for celiac disease. Esophagogastroduodenoscopy and distal duodenal biopsy in patients with diarrhea, to rule out celiac disease, tropical sprue, giardiasis, and in patients in whom abdominal pain and discomfort is located more in the upper abdomen. Colonoscopy and biopsy. Fecal inflammation marker (eg, calprotectin or lactoferrin) to distinguish IBS from inflammatory bowel disease (IBD) where the latter is prevalent. Hydrogen breath test for lactose intolerance and small-intestinal bacterial overgrowth (SIBO). Medium Resource Levels History, physical examination, exclusion of alarm symptoms, consideration of psychological factors. FBC, ESR or CRP, stool studies, thyroid function. Sigmoidoscopy. Low Resource Levels History, physical examination, exclusion of alarm symptoms, consideration of psychological factors. FBC, ESR, and stool examination. Note: Even in “wealthy” countries, not all patients need colonoscopy, which should be reserved in particular for those with alarm symptoms or signs and those over the age of 50. The need for investigations and for sigmoidoscopy and colonoscopy, in particular, should also be dictated by the characteristics of the patient (presenting features, age, etc.) and the geographical location (ie, whether or not in an area of high prevalence for IBD, celiac disease, colon cancer, or parasitosis). In general, the diagnosis is “safer” in patients with constipation, whereas in patients with severe diarrhea, there is a greater need to consider tests to exclude organic pathology. Cascade Options for Resource-sensitive IBS Management High Resource Levels Reassurance, dietary and lifestyle review, and counseling. Try a quality probiotic with proven efficacy. Symptomatic treatment of: Pain, with a locally available antispasmodic; for more severely affected patients, a low-dose tricyclic antidepressant (TCA) or selective serotonin reuptake inhibitor (SSRI) should be added. Constipation with dietary measures and fiber supplementation, progressing to osmotic laxatives such as lactulose. Although the evidence to support their use is weak, it may be worth addressing diarrhea with simple antidiarrheals. Psychological approaches (hypnotherapy, psychotherapy, group therapy) should be considered and consultation with a dietitian, where indicated. Add specific pharmacological agents, where approved: Lubiprostone or linaclotide for IBS with constipation (IBS-C). Rifaximin for diarrhea and bloating. Alosetron and eluxadoline for IBS with diarrhea (IBS-D). Medium Resource Levels Reassurance, dietary and lifestyle review, and counseling. Add a quality probiotic with proven efficacy. Symptomatic treatment of: Pain, with a locally available antispasmodic; for more severely affected patients, a low-dose TCA should be added. Constipation with dietary measures and fiber supplementation. Although the evidence to support their use is weak, it may be worth addressing diarrhea with bulking agents and simple antidiarrheals. Low Resource Levels Reassurance, dietary and lifestyle review, and counseling. Symptomatic treatment of: Pain, with a locally available antispasmodic. Constipation, with dietary measures and fiber supplementation. Although the evidence to support their use is weak, it may be worth addressing diarrhea with bulking agents and simple antidiarrheals. INTRODUCTION Definition: IBS is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation and/or a change in bowel habit. Sensations of discomfort (bloating), distension, and disordered defecation are commonly associated features. In some languages, the words “bloating” and “distension” may be represented by the same term. IBS is not known to be associated with an increased risk for the development of cancer or IBD, or with increased mortality. It generates significant direct and indirect health care costs. Although visceral hypersensitivity is accepted as prevalent, no universal pathophysiological substrate has been demonstrated in IBS.1 A transition of IBS to, and overlap with, other symptomatic gastrointestinal disorders (eg, gastroesophageal reflux disease, dyspepsia, and functional constipation) may occur. IBS usually causes long-term symptoms, which may occur in episodes. Symptoms vary and are often associated with f
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728
Self-citationAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Self-citationWEDLAKE, L., A’HERN, R., RUSSELL, D., THOMAS, K., WALTERS, J. R. F., & ANDREYEV, H. J. N. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04081.x · Cited by 435
The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Brenner, D. M., Moeller, M. J., Chey, W. D., & Schoenfeld, P. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.25 · Cited by 362
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Ford, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261
Slattery, S. A., Niaz, O., Aziz, Q., Ford, A. C., & Farmer, A. D. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13227 · Cited by 214
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
Self-citationSchaefert, R., Klose, P., Moser, G., & Häuser, W. (2014) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000039 · Cited by 103
Lovell, R. M., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.336 · Cited by 95
Cited by
Dietary fibre in gastrointestinal health and disease
Gill, S. K., Rossi, M., Bajka, B., & Whelan, K. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00375-4 · Cited by 979
The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity
Cerdó, T., García-Santos, J., G. Bermúdez, M., & Campoy, C. (2019) · Nutrients · doi:10.3390/nu11030635 · Cited by 401
Hunt, R., Armstrong, D., Katelaris, P., Afihene, M., Bane, A., Bhatia, S., Chen, M.-H., Choi, M. G., Melo, A. C., Fock, K. M., et al. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000854 · Cited by 306
Self-citationIrritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice
Moayyedi, P., Mearin, F., Azpiroz, F., Andresen, V., Barbara, G., Corsetti, M., Emmanuel, A., Hungin, A. P. S., Layer, P., Stanghellini, V., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617731968 · Cited by 135
“whether pain is relieved with bowel movements.(4,20) Other abdominal symptoms that are consistent with a diagnosis of IBS (but not present in all patients) include bloating, distention and flatulence.”
BackgroundSelf-citationShang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., et al. (2022) · Nutrients · doi:10.3390/nu14122482 · Cited by 41
Metadata
- Authors
- Quigley, E. M. M., Fried, M., Gwee, K.-A., Khalif, I., Hungin, A. P. S., Lindberg, G., Abbas, Z., Fernandez, L. B., Bhatia, S. J., Schmulson, M., Olano, C., & LeMair, A.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2016-10
- Volume
- 50
- Issue
- 9
- Pages
- 704-713
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2518991284
- Cited by
- 126
- References
- 12
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.